Male fertility overview and risk factors

Understanding male fertility

Male fertility is the capacity to contribute sperm that can fertilize an egg and support the earliest steps of embryo development. Biologically, this requires coordinated function of the hypothalamus-pituitary-testes axis, the testes, epididymides, vas deferens, accessory glands, erectile and ejaculatory mechanisms, and the reproductive tract of the partner. A difficulty in any one part of this pathway can lower the probability of conception.

Sperm production, or spermatogenesis, occurs in the seminiferous tubules of the testes and takes roughly several months from early germ cell development to mature sperm available in the ejaculate. This means that recent fever, medication exposure, toxin exposure, or lifestyle changes may influence semen parameters weeks to months later rather than immediately. Sperm production and maturation continue in the epididymis, where sperm acquire improved motility and fertilizing capacity.

Clinically, male factor infertility does not mean a person is infertile in every circumstance. Fertility is probabilistic: semen quality, timing of intercourse, ovulation, tubal function, uterine factors, and age of the partner all interact. Some men with abnormal semen analysis results conceive without treatment, while others with borderline findings may need assisted reproductive technology depending on the broader couple-based picture.

How male fertility is assessed

The usual first test is a semen analysis, ideally performed according to laboratory instructions after an appropriate abstinence interval. Because semen parameters vary from sample to sample, a single abnormal result is rarely the final answer. Clinicians often repeat testing and interpret findings in relation to history, physical examination, and partner factors.

Core semen parameters include semen volume, sperm concentration, total sperm count, motility, progressive motility, and morphology. Semen volume may point toward ejaculatory duct obstruction, retrograde ejaculation, androgen deficiency, or collection issues. Sperm concentration and total count describe how many sperm are present. Sperm motility and morphology provide information about movement and shape, though morphology can be technically variable and should not be overinterpreted in isolation.

Evaluation may also include a focused reproductive history, examination of testicular size and consistency, assessment for varicocele, review of medications and supplements, endocrine testing, genetic testing in selected cases, and imaging when obstruction or structural disease is suspected. Severe oligozoospermia or azoospermia generally warrants referral to a reproductive urologist, because treatable endocrine, obstructive, genetic, or surgical factors may be present.

Medical and anatomical risk factors

Several medical and anatomical conditions are associated with impaired semen quality or reduced fertility. Varicocele, a dilation of veins in the scrotum, is a common finding in male infertility evaluations and may be linked with poorer sperm concentration, motility, morphology, and testicular function in some patients. Whether treatment is appropriate depends on symptoms, semen findings, testicular size, reproductive goals, and the couple’s overall fertility context.

Infections and inflammation can affect fertility through direct injury, obstruction, oxidative stress, or impaired accessory gland function. Sexually transmitted infections, epididymitis, orchitis, prostatitis, and a history of mumps orchitis are examples clinicians may ask about. Prompt treatment of infections and prevention through safer sex practices may reduce some risks, but past infection-related injury may require specialist evaluation.

Obstruction can occur after vasectomy, hernia repair, scrotal or pelvic surgery, infection, congenital absence of the vas deferens, or ejaculatory duct abnormalities. In obstructive azoospermia, sperm production may be adequate, but sperm cannot reach the ejaculate. Non-obstructive azoospermia, by contrast, reflects absent or severely impaired sperm production. Distinguishing these patterns is important because testing, counseling, and treatment options differ.

Chronic illnesses may also affect fertility. Diabetes can contribute through ejaculatory dysfunction, neuropathy, oxidative stress, and metabolic changes. Metabolic syndrome and obesity are associated in research with poorer semen parameters and hormonal alterations, including lower testosterone and changes in gonadotropin signaling. Kidney disease, liver disease, thyroid disorders, inflammatory diseases, and severe systemic illness may also influence reproductive function.

Hormonal, genetic, and developmental factors

Normal sperm production depends on appropriate signaling from gonadotropin-releasing hormone, luteinizing hormone, follicle-stimulating hormone, intratesticular testosterone, and Sertoli cell function. Endocrine disorders such as hypogonadotropic hypogonadism, hyperprolactinemia, thyroid disease, and pituitary disorders can reduce sperm production or sexual function. Because some endocrine causes are treatable, hormonal causes of male infertility deserve careful medical evaluation rather than self-treatment.

Developmental history matters. Undescended testes, especially if bilateral or corrected late, are associated with increased risk of impaired spermatogenesis. Testicular torsion, trauma, orchitis, chemotherapy, radiation, and prior testicular cancer can also reduce sperm-producing capacity. Men who may need cancer therapy should ask urgently about fertility preservation before cancer treatment, because sperm banking before treatment can preserve future options.

Genetic factors are particularly important in severe oligozoospermia and azoospermia. Examples include Klinefelter syndrome, Y-chromosome microdeletions, chromosomal rearrangements, and CFTR-related congenital bilateral absence of the vas deferens. Genetic testing for male infertility may inform prognosis, guide sperm retrieval decisions, identify health implications for the patient, and clarify inheritance risks. Results should be discussed with clinicians experienced in reproductive genetics, especially before assisted reproduction.

Lifestyle and body-related risk factors

Lifestyle does not explain every fertility problem, and infertility should never be framed as a personal failure. Still, several behaviors are consistently discussed in the evidence base because they may influence semen quality, hormonal balance, erectile function, or general reproductive health.

• Smoking: Cigarette smoking is associated with poorer semen parameters in many studies and may increase oxidative stress affecting sperm function.
• Alcohol: Heavy alcohol use may impair testosterone production, liver metabolism of hormones, sexual function, and sperm quality. Low or occasional intake has less certain effects, but reducing heavy use is generally advisable for overall health.
• Obesity: Higher body mass index is linked with altered reproductive hormones, inflammation, oxidative stress, erectile dysfunction, and poorer semen parameters in some analyses.
• Illicit and anabolic drugs: Anabolic-androgenic steroids and some performance-enhancing drugs can suppress the hypothalamus-pituitary-testes axis and may cause severe oligozoospermia or azoospermia. Cannabis, opioids, cocaine, and other substances have been studied with mixed but concerning findings depending on dose and context.
• Heat exposure: Frequent high heat around the testes, such as hot tubs, saunas, prolonged laptop placement on the lap, or certain occupational settings, may temporarily affect sperm production in susceptible individuals.

General health measures such as regular physical activity, adequate sleep, balanced nutrition, and treatment of metabolic disease may support reproductive health, but they are not substitutes for evaluation when infertility persists. Supplements marketed for sperm health should be discussed with a clinician, especially because product quality, interactions, and evidence vary.

Medications, toxins, and environmental exposures

Medication review is an essential part of male fertility evaluation. Testosterone therapy and sperm production are closely linked: exogenous testosterone can suppress pituitary gonadotropins and markedly reduce intratesticular testosterone, which is necessary for spermatogenesis. Some men taking prescribed testosterone are surprised to learn it can lower sperm counts. Other medications that may affect fertility in selected circumstances include certain chemotherapies, radiation exposure, antiandrogens, some antidepressants, opioids, 5-alpha-reductase inhibitors, spironolactone, sulfasalazine, and some immunosuppressants. Never stop a prescribed medication without medical guidance; safer alternatives or fertility-preserving strategies may be available.

Occupational and environmental exposures are also relevant. Pesticides, solvents, heavy metals, endocrine-disrupting chemicals, industrial heat, ionizing radiation, and air pollutants have been associated in research with adverse semen parameters or reproductive risk. The magnitude of risk depends on dose, duration, protective equipment, and coexisting factors. People working in agriculture, manufacturing, painting, welding, laboratories, or radiation environments should mention these exposures during fertility visits.

Practical risk reduction may include using appropriate protective equipment, following workplace safety procedures, avoiding direct heat to the scrotum when possible, and discussing high-risk exposures with occupational health professionals. Because many associations come from observational studies, clinicians usually interpret exposure history as one part of a broader assessment rather than as a stand-alone diagnosis.

Age, timing, and when to seek help

Male age is not a strict fertility cutoff, but increasing paternal age is associated in the literature with changes in semen parameters, longer time to pregnancy in some couples, and higher rates of certain genetic and pregnancy-related risks. The effect is usually more gradual than age-related decline in ovarian reserve, but it is still clinically relevant, especially when combined with partner age or other fertility factors.

A common recommendation is to seek fertility evaluation after 12 months of regular, unprotected intercourse without pregnancy, or after 6 months if the female partner is 35 or older. Earlier assessment is reasonable when there is known azoospermia, prior vasectomy, chemotherapy or radiation, undescended testes, testicular surgery, erectile or ejaculatory dysfunction, recurrent pregnancy loss, very irregular ovulation in the partner, or significant pelvic, scrotal, or endocrine history.

Fertility care is most supportive when it is couple-based care rather than blame-based care. Male evaluation is often less invasive and less costly than many female fertility tests, and identifying male factors early can prevent delays. Even when a risk factor is present, a healthcare professional can help clarify which findings are clinically meaningful and which steps are appropriate for the couple’s goals.